Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas

Francesca Marciello, Carolina Di Somma, Michela Del Prete, Vincenzo Marotta, Valeria Ramundo, Annachiara Carratù, Chiara De Luca Di Roseto, Luigi Camera, Annamaria Colao, Antongiulio Faggiano

Research output: Contribution to journalArticle

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome associated with the development of many endocrine tumors, involving mainly pituitary, parathyroids, pancreas, although a proliferative state interests all neuroendocrine system. MEN1 pancreatic neuroendocrine tumors (pNETs) are multiples and can secrete different hormones. The therapeutic approach is based on surgery which usually is followed by tumor relapse or persistence unless to be highly aggressive. Biotherapy with somatostatin analogs and dopamine agonists could be of great benefit to manage these patients without altering their life quality. We report a case of a 36-year-old MEN1 man affected with multicentric pNETs associated with insulinoma syndrome. Therapy with symptomatic agents (diazoxide), as well as biotherapy (lanreotide, cabergoline) was started. At 6-month follow-up, symptomatic agents were stopped and disease control was only based on lanreotide plus cabergoline. This combined biotherapy was able to control endocrine syndromes and tumor growth. Subsequently, a safer and selective surgical intervention on pNETs was performed. An excellent response to therapy with lanreotide autogel and cabergoline has been observed in a MEN1 patient with pNETs associated with insulinoma syndrome. The potential synergistic effects of lanreotide autogel and cabergoline on insulin-secreting neuroendocrine tumors are discussed.

Original languageEnglish
Pages (from-to)678-681
Number of pages4
JournalEndocrine
Volume46
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • Dopamine agonists
  • Insulinoma syndrome
  • MEN1 syndrome
  • Neuroendocrine tumors
  • Somatostatin analogs

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Fingerprint Dive into the research topics of 'Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas'. Together they form a unique fingerprint.

  • Cite this

    Marciello, F., Di Somma, C., Del Prete, M., Marotta, V., Ramundo, V., Carratù, A., De Luca Di Roseto, C., Camera, L., Colao, A., & Faggiano, A. (2014). Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. Endocrine, 46(3), 678-681. https://doi.org/10.1007/s12020-013-0145-2